ATAZANAVIR

Product NDC
70710-1052
11-digit product format
707101052
Labeler code
70710
Product ID
70710-1052_eba93fa3-287b-4174-b304-a9f262e900de
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
ATAZANAVIR
Dosage form
CAPSULE
Route
ORAL
Labeler
Zydus Pharmaceuticals USA Inc.
Application
ANDA210575
Marketing category
ANDA
Marketing start
2021-05-04
Marketing end
0000-00-00
Substance
ATAZANAVIR SULFATE
Active strength
300 mg/1
Pharmacologic classes
Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2023-12-31
Current FDA listing
Historical FDA.report record

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
70710-1052ATAZANAVIR CAPSULE [ZYDUS PHARMACEUTICALS USA INC.]3Legacy NDC20230516_a40c4633-1808-4a28-b4af-769fb36da6c5.zip

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
70710-1052-170710105201100 CAPSULE in 1 BOTTLE (70710-1052-1) 100 capsule2021-05-040000-00-00NoNoCurrent
70710-1052-37071010520330 CAPSULE in 1 BOTTLE (70710-1052-3) 30 capsule2021-05-040000-00-00NoNoCurrent